Abstract
Executive Summary
This report aims to analyze the current and future potential of breast cancer
pipeline by examining key fundamentals across the entire pipeline of drug
candidates. BioSeeker has identified three fundamental dimensions to outline
the competitive landscape within the pharmaceutical industry; compound type,
therapy area and target type.
This report is written for you to identify your competition and understand
which targeting strategies are at work within breast cancer drug development.
It allows you to pin-point which competitors drugs' clinical out-come may have
bearing on your own drug development and who are developing sequels to
blockbuster drugs. This report also helps you to locate white-spots in the
competitive landscape, giving you little or no competition. Conversely it may
reveal unexpected competition for you.
Drug targets are the critical link between drugs and their role in the
treatment of medical disorders. BioSeeker has surveyed the breast cancer field
and identified 148 drug targets belonging to 243 drugs. This report, Currently
Druggable in Breast Cancer: A Drug Target Competitive Analysis is an open
landscape of resources to build, fuel, and drive your scientific competitive
vehicle for the advancement of breast cancer drugs.
In the report, BioSeeker reports on 130 unique drug target combinations, each
comprised of a different collection or mix of individually defined targets,
for 243 breast cancer drugs. The highest degree of distinctiveness among the
cancer drugs is achieved by sorting each of them according to drug target mix,
compound type and therapy strategy. At the same time we are also identifying
peer groups of drugs, that is, drugs we consider suitable for head-to-head
comparison during drug development.
To fuel the scientific and competitive thinking, BioSeeker opens the gate into
the presence and relevance of protein-protein interactions between identified
targets of breast drugs. No less than 311 protein-protein interactions were
recognized among and between 114 of the 143 included breast cancer drug
targets.
Why You Should Own Your Own Copy of this Report:
- 310+ pages, with more than 60 different tables and figures. Includes more
than 1,000 active links to drug target related resources on the Internet.
- A 243 breast cancer drugs analysis, under development by 152 investigators.
- 148 unique, in-depth, drug target validating profiles, highlighting twelve
themes about the drug target, i.e. protein-protein interaction with other
breast cancer drug targets, pursued cancer indications, drugs under
development, presence in the Cancer Genome Project etc.
- A unique drug target combination breakdown of breast cancer drugs into
major therapy strategies.
- Unique drug-protein target interactome- and protein-protein interactome of
drug targets analysis.
- Pathway profiling of breast cancer drug targets.
- Pin-point which competitor drugs' clinical out-come may have bearing on
your own drug development.
- Who are working on sequels to blockbuster drugs?
- Locate white-spots in the competitive landscape, giving you little or no
competition.
- In all, this report is a serious reference for any professional interested
in the development of oncology drug targets and the selection/validation of
targeting strategies.
| 
View Cart
